Literature DB >> 27190870

Biphasic Effect of Rifampicin on Bilirubin- A Case Report.

Manigandan Gopi1, Mandalam Subramanian Seshadri2.   

Abstract

Drug induced hepatitis is a major problem which a physician encounters in his clinical practice. In view of increasing incidence of tuberculosis in our country a large number of infected individuals are started on Antituberculous (ATT) drugs and rifampicin is invariably part of the regimen. One of the major adverse effects of ATT drugs is drug- induced hepatitis which is characterized by elevation of liver enzymes and bilirubin. Hepatotoxicity is usually idiosyncratic or dose-dependent. Rifampicin causes transient elevation of transaminases in 10-20 percent of individuals and this does not warrant dose adjustments of the drug. Rarely rifampicin can lead to severe hepatitis with hyperbilirubinaemia and marked elevations of SGOT and SGPT and in some patients this can be fatal. The exact mechanism of Rifampicin induced hepatotoxicity is not known but it is postulated to be due to idiosyncratic reaction to rifampicin metabolites which may be directly toxic or induce an immunologically mediated liver injury. Rarely rifampicin may cause hyperbilirubinaemia without enzyme elevation. Here we report a patient with bilateral pulmonary tuberculosis who developed transient severe indirect hyperbilirubinaemia on rifampicin. On review of relevant literature we find that rifampicin can have a biphasic effect on bilirubin, an initial increase in indirect bilirubin and later normalization of bilirubin. We have reported this case because of its rarity in clinical practice.

Entities:  

Keywords:  Antitubercular drugs; Drug induced hepatitis; Hyperbilirubinaemia

Year:  2016        PMID: 27190870      PMCID: PMC4866168          DOI: 10.7860/JCDR/2016/18040.7614

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  6 in total

1.  Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.

Authors:  Surendra K Sharma; Arumugam Balamurugan; Pradip Kumar Saha; Ravindra M Pandey; Narinder K Mehra
Journal:  Am J Respir Crit Care Med       Date:  2002-10-01       Impact factor: 21.405

Review 2.  Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors:  C Bénichou
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

3.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

4.  Effect of rifampicin on haem and bilirubin metabolism in man.

Authors:  K E McColl; G G Thompson; E el Omar; M R Moore; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

6.  Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein.

Authors:  S Kenwright; A J Levi
Journal:  Gut       Date:  1974-03       Impact factor: 23.059

  6 in total
  1 in total

Review 1.  Monitoring Treatment of Childhood Tuberculosis and the Role of Therapeutic Drug Monitoring.

Authors:  Andrea T Cruz; Jeffrey R Starke
Journal:  Indian J Pediatr       Date:  2019-02-28       Impact factor: 5.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.